The use of proton pump inhibitors in patients admitted to intensive care units: an integrative review
DOI:
https://doi.org/10.33448/rsd-v11i14.36763Keywords:
Intensive Care Unit; Proton pump inhibitors; Drug therapy.Abstract
Critical patients admitted to Intensive Care Units (ICU) are at high risk for developing stress ulcers or gastrointestinal bleeding, so there are recommendations on the use of prophylactic drugs for this event, such as proton pump inhibitors in these patients. Therefore, this study aims to analyze the literature on the effects of proton pump inhibitors use in patients admitted to intensive care units. In this sense, articles were collected in the MEDLINE databases, through the search engine Public/Publisher MEDLINE (PubMed) and BVS - Virtual Health Library -. The descriptors of interest found through the Medical Subject Headings (MeSH) tool were “Proton Pump Inhibitors” AND “Intensive Care Unit”, which were selected based on previous publications on the object of study and combined in the strategy of elucidated search. 16 of the 553 articles found with the search were included in this review. Furthermore, there was an analysis of the level of evidence and the degree of recommendation of the articles according to the Oxford Center Evidence-Based Medicine system. It is concluded, according to the studies analyzed, that there is divergence in the literature regarding the definition of the effects of this drug class in ICU patients, in which outcomes such as bloodstream infection, pneumonia, mortality, and superiority in preventing bleeding provided by the use of proton pump inhibitors is not fully in agreement among the articles studied. Thus, further studies are needed to understand the effects of proton pump inhibitors in ICU patients.
References
al Sulaiman, K., al Aamer, K., al Harthi, A., Jaser, S., al Anazi, A., al Subaie, S., & Vishwakarma, R. (2020). Comparison between esomeprazole 20 mg Vs 40 mg as stress ulcer prophylaxis (SUP) in critically ill patients: A retrospective cohort study. Pharmacology Research and Perspectives, 8(4). https://doi.org/10.1002/prp2.624
Alhazzani, W., Alshamsi, F., Belley-Cote, E., Heels-Ansdell, D., Brignardello-Petersen, R., Alquraini, M., Perner, A., Møller, M. H., Krag, M., Almenawer, S., Rochwerg, B., Dionne, J., Jaeschke, R., Alshahrani, M., Deane, A., Perri, D., Thebane, L., Al-Omari, A., Finfer, S., Cook, D., … Guyatt, G. (2018). Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive care medicine, 44(1), 1–11. https://doi.org/10.1007/s00134-017-5005-8
Bischoff, L. M., Faraco, L. S. M., Machado, L. v., Bialecki, A. V. S., de Almeidai, G. M., & Beckers, S. C. C. (2021). Inappropriate usage of intravenous proton pump inhibitors and associated factors in a high complexity hospital in brazil. Arquivos de Gastroenterologia, 58(1), 32–38. https://doi.org/10.1590/s0004-2803.202100000-07
Catano, J., Sacleux, S. C., Gornet, J. M., Camus, M., Bigé, N., Saliba, F., Azoulay, E., Dumas, G., & Zafrani, L. (2021). Gastrointestinal bleeding in critically ill immunocompromised patients. Annals of Intensive Care, 11(1). https://doi.org/10.1186/s13613-021-00913-6
Cohen, M. E., Hathway, J. M., Salmasian, H., Liu, J., Terry, M., Abrams, J. A., & Freedberg, D. E. (2017). Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit. Clinical Gastroenterology and Hepatology, 15(7), 1030-1036.e1. https://doi.org/10.1016/j.cgh.2016.12.035
Gündoğan, K., Karakoç, E., Teke, T., Zerman, A., Esmaoğlu, A., Temel, Ş., Güven, M., & Sungur, M. (2020). Effects of oral/enteral nutrition alone versus plus pantoprazole on gastrointestinal bleeding in critically ill patients with low risk factor: A multicenter, randomized controlled trial. Turkish Journal of Medical Sciences, 50(4), 776–783. https://doi.org/10.3906/sag-1911-42
Hailstone, E., Falkos, S., Vidal, R., Jones, K. A., Gaillard, P. R., Fan, S., & Chung, A. M. (2021). Impact of acid suppression therapy on iron supplementation in the pediatric intensive care unit. Journal of Pediatric Pharmacology and Therapeutics, 26(4), 366–371. https://doi.org/10.5863/1551-6776-26.4.366
Huang, M., Han, M., Han, W., & Kuang, L. (2021). Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study. Journal of International Medical Research, 49(6). https://doi.org/10.1177/03000605211025130
Kanno, T., & Moayyedi, P. (2020). Who Needs Gastroprotection in 2020? Current Treatment Options in Gastroenterology, 18(4), 557–573. https://doi.org/10.1007/s11938-020-00316-9
Krag, M., Marker, S., Perner, A., Wetterslev, J., Wise, M. P., Schefold, J. C., Keus, F., Guttormsen, A. B., Bendel, S., Borthwick, M., Lange, T., Rasmussen, B. S., Siegemund, M., Bundgaard, H., Elkmann, T., Jensen, J. v., Nielsen, R. D., Liboriussen, L., Bestle, M. H., … Møller, M. H. (2018). Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. New England Journal of Medicine, 379(23), 2199–2208. https://doi.org/10.1056/nejmoa1714919
Krzych, Ł. J., Łój, P., Nowak, T., Kazura, W., & Knapik, P. (2017). Short-term proton pump inhibitor treatment may cause hypomagnesaemia in critically ill patients - A pilot study. Acta Biochimica Polonica, 64(3), 499–501. https://doi.org/10.18388/abp.2017_1505
Li, F., Liu, H., Zhang, L., Huang, X., Liu, Y., Li, B., Xu, C., Lyu, J., & Yin, H. (2022). Effects of Gastric Acid Secretion Inhibitors for Ventilator-Associated Pneumonia. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.898422
Lilly, C. M., Aljawadi, M., Badawi, O., Onukwugha, E., Tom, S. E., Magder, L. S., & Harris, I. (2018). Comparative Effectiveness of Proton Pump Inhibitors vs Histamine Type 2 Receptor Blockers for Preventing Clinically Important Gastrointestinal Bleeding During Intensive Care: A Population-Based Study. Chest, 154(3), 557–566. https://doi.org/10.1016/j.chest.2018.05.015
Marker, S., Krag, M., & Møller, M. H. (2017). What’s new with stress ulcer prophylaxis in the ICU? Intensive Care Medicine, 43(8), 1132–1134. https://doi.org/10.1007/s00134-017-4733-0
Marker, S., Perner, A., Wetterslev, J., Barbateskovic, M., Jakobsen, J. C., Krag, M., Granholm, A., Anthon, C. T., & Møller, M. H. (2017). Stress ulcer prophylaxis versus placebo or no prophylaxis in adult hospitalized acutely ill patients-protocol for a systematic review with meta-analysis and trial sequential analysis. Systematic Reviews, 6(1). https://doi.org/10.1186/s13643-017-0509-4
Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) — Centre for Evidence-Based Medicine (CEBM), University of Oxford. (s.d.). Home — Centre for Evidence-Based Medicine (CEBM), University of Oxford. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
Saad, M., & Mitwally, H. (2020). Lansoprazole-Induced Thrombocytopenia in a Critically Ill Patient: A Case Report. Journal of Pharmacy Practice, 33(5), 700–704. https://doi.org/10.1177/0897190019838681
Song, M. J., Kim, S., Boo, D., Park, C., Yoo, S., Yoon, H. il, & Cho, Y. J. (2021). Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-98069-7
Souza, M. T., Silva, M. D., Carvalho, R. Revisão integrativa: o que é e como fazer. Einstein, 2010. 8(1), 102-106. http://www. astresmetodologias.com/material/O_que_e_RIL.pdf
Souza, R. S. M., Junior, G. L. A., Neves, V. H. D., Pereira, V. M., & Burgos, U. M. M. C. (2021). A infecção por coronavírus e a cardiomiopatia de Takotsubo na era da pandemia do SARS-CoV 2. Revista Eletrônica Acervo Científico, 25. https://doi.org/10.25248/reac.e7368.2021
Tian, H., Xu, Y., Wang, J., Tian, W., Sun, J., Zhang, T., Zhou, Q., & Shao, C. (2018). Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients. BioMed Research International, 2018. https://doi.org/10.1155/2018/6374374
Toews, I., George, A. T., Peter, J. v., Kirubakaran, R., Fontes, L. E. S., Ezekiel, J. P. B., & Meerpohl, J. J. (2018). Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. In Cochrane Database of Systematic Reviews (Vol. 2018, Issue 6). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD008687.pub2
Xu, Y., Tian, X., Wang, W., Tian, W., Zhang, T., Sun, J., Zhou, Q., & Shao, C. (2022). Pharmacokinetics of Esomeprazole in Critically Ill Patients. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.621406
Young, P. J., Bagshaw, S. M., Forbes, A. B., Nichol, A. D., Wright, S. E., Bailey, M., Bellomo, R., Beasley, R., Brickell, K., Eastwood, G. M., Gattas, D. J., van Haren, F., Litton, E., MacKle, D. M., McArthur, C. J., McGuinness, S. P., Mouncey, P. R., Navarra, L., Opgenorth, D., & Rowan, K. M. (2020). Effect of Stress Ulcer Prophylaxis with Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 323(7), 616–626. https://doi.org/10.1001/jama.2019.22190
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Gledson Lima Alves Junior; Genivaldo Galindo Neto; Rodrigo Cardoso de Oliveira; Julianne Pitanga Teixeira; Marina Maria Santos Alves Alves; Vitor Moura Pereira Pereira; Matheus Alves Nunes Carvalho Carvalho; Victor Lucas de Santana Cardoso Cardoso; André Luiz Baião Campos Campos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
